EP Wealth Advisors LLC Increases Position in Boston Scientific Co. (NYSE:BSX)

EP Wealth Advisors LLC lifted its position in shares of Boston Scientific Co. (NYSE:BSX) by 4.1% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 13,066 shares of the medical equipment provider’s stock after purchasing an additional 514 shares during the period. EP Wealth Advisors LLC’s holdings in Boston Scientific were worth $1,006,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently modified their holdings of the company. Eagle Bay Advisors LLC lifted its holdings in Boston Scientific by 542.1% during the 1st quarter. Eagle Bay Advisors LLC now owns 366 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 309 shares during the last quarter. First Foundation Advisors purchased a new stake in Boston Scientific during the first quarter worth approximately $25,000. Triad Wealth Partners LLC acquired a new position in Boston Scientific in the second quarter valued at approximately $26,000. Andra AP fonden purchased a new position in Boston Scientific in the second quarter valued at approximately $29,000. Finally, RiverPark Advisors LLC acquired a new stake in Boston Scientific during the first quarter worth approximately $30,000. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In other news, EVP Wendy Carruthers sold 6,983 shares of the company’s stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $83.86, for a total transaction of $585,594.38. Following the transaction, the executive vice president now directly owns 34,748 shares of the company’s stock, valued at approximately $2,913,967.28. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Over the last quarter, insiders sold 20,949 shares of company stock valued at $1,673,685. 0.50% of the stock is owned by company insiders.

Boston Scientific Trading Up 0.4 %

Shares of Boston Scientific stock opened at $84.47 on Thursday. The company has a quick ratio of 1.14, a current ratio of 1.61 and a debt-to-equity ratio of 0.44. The firm has a market cap of $123.93 billion, a price-to-earnings ratio of 70.98, a price-to-earnings-growth ratio of 2.78 and a beta of 0.79. Boston Scientific Co. has a 52-week low of $48.35 and a 52-week high of $84.89. The company’s 50-day simple moving average is $79.69 and its 200-day simple moving average is $75.62.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, July 24th. The medical equipment provider reported $0.62 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.58 by $0.04. Boston Scientific had a return on equity of 16.59% and a net margin of 12.00%. The business had revenue of $4.12 billion during the quarter, compared to the consensus estimate of $4.02 billion. During the same period in the prior year, the business posted $0.53 EPS. The company’s revenue for the quarter was up 14.5% on a year-over-year basis. As a group, equities research analysts anticipate that Boston Scientific Co. will post 2.4 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently issued reports on BSX. Evercore ISI upped their target price on shares of Boston Scientific from $82.00 to $90.00 and gave the company an “outperform” rating in a report on Tuesday. StockNews.com downgraded shares of Boston Scientific from a “buy” rating to a “hold” rating in a research note on Tuesday, September 24th. Truist Financial lifted their target price on Boston Scientific from $86.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, July 16th. BTIG Research upped their target price on Boston Scientific from $80.00 to $84.00 and gave the company a “buy” rating in a research report on Monday, July 15th. Finally, Canaccord Genuity Group lifted their price target on Boston Scientific from $83.00 to $88.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Three investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $87.10.

Boston Scientific Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.